Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly and Company discovers, develops ... as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...